Navigation Links
New Analyses Presented at ASCO Reaffirmed Efficacy and Safety of TORISEL in Patients With Advanced Kidney Cancer
Date:5/31/2008

- Data Showed Overall Survival Benefit With TORISEL Regardless of Nephrectomy Status; Additional Analysis Examined Specific Side Effects -

COLLEGEVILLE, Pa., May 31 /PRNewswire-FirstCall/ -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), today announced results of two new analyses of the pivotal study of the mTOR (mammalian target of rapamycin) inhibitor TORISEL(R) (temsirolimus), the only renal cancer therapy proven to extend median overall survival compared with interferon-alpha in patients with advanced renal cell carcinoma (RCC). These analyses, which are being presented at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, reaffirm the efficacy and safety of TORISEL for the treatment of advanced RCC. TORISEL is the only approved cancer therapy that specifically inhibits the mTOR kinase, an important regulator of cell proliferation, cell growth and cell survival.

RCC will account for approximately 85 percent of renal cancers. There are an estimated 54,390 new cases of kidney and renal pelvis cancer diagnosed in the United States each year, and about 40 percent of patients have advanced disease at the time of diagnosis.

TORISEL was studied in a three-arm, phase 3 clinical trial of 626 patients with advanced RCC with three or more of six preselected prognostic risk factors who had received no prior systemic therapy. Results of this study demonstrated that TORISEL significantly increased median overall survival by 49 percent compared with interferon-alpha (10.9 months [95% CI: 8.6, 12.7] vs. 7.3 months [6.1, 8.8], P=0.0078) (Hazard Ratio [95% CI] = 0.73 [0.58, 0.92]).

"In summary, these analyses provide clinicians with additional information about the efficacy an
'/>"/>

SOURCE Wyeth Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. New MIRCERA(R) Data Analyses to be Featured at the American Society of Nephrology Annual Meeting
2. New Analyses of Long-Term LIALDA(TM) (mesalamine) Data Presented at ACG
3. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
4. Xeloda(R) XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
5. Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
6. Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
7. Data To Be Presented at ASCO Supports Potential of Peregrines Cotara(R) for the Treatment of Brain Cancer
8. About 60 Clinical Studies Regarding Schering-Ploughs Oncology Compounds Will be Presented at ASCO
9. Two DOXIL(R) Studies to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting
10. Treprostinil Data Presented at American Thoracic Society Conference Demonstrates Significant Clinical Progress in All Four Routes of Administration
11. Safety and Efficacy Results Presented From Largest Prospective Controlled Clinical Study of Ulcerative Colitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... a special edition of #MedicareMonday on Medicare,s 50 th anniversary. As Medicare celebrates ... continue highlighting the success of the prescription drug benefit, commonly referred to as Part ... infographics and videos here: http://onphr.ma/1INp9qQ ... ... ...
(Date:7/30/2015)... THOUSAND OAKS, Calif. , July 30, 2015  Amgen ... Fred Hassan , partner and managing director of Warburg Pincus ... "We are pleased to welcome Fred Hassan and ... to the Amgen Board," said Robert A. Bradway , ... expertise and commitment to innovation will serve Amgen well." ...
(Date:7/30/2015)... VALLEY COTTAGE, New York , July 30, 2015 ... the release of its latest report titled, "Continuous Glucose ... 2015 - 2020". According to the report, the global ... 402.0 Mn in 2014 and is expected to reach ... 12.1% during the forecast period, 2015 to 2020. ...
Breaking Medicine Technology:Happy 50th Anniversary Medicare! 2Happy 50th Anniversary Medicare! 3Amgen Announces Appointment Of Fred Hassan To Board Of Directors 2Amgen Announces Appointment Of Fred Hassan To Board Of Directors 3Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 2Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 3Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 4
... SEATTLE, Feb. 10 Cell Therapeutics (CTI) (NASDAQ and ... definitive collaborative agreement with IDIS to manage its investigational ... Pixantrone will be supplied by IDIS to healthcare ... aggressive non-Hodgkin,s lymphoma. This program is expected to ...
... MONTREAL, Feb. 9 Sequoia Pharmaceuticals presented,positive ... in healthy volunteers and,preclinical studies on SPI-452, ... antiviral activity. Pharmacokinetic enhancers increase drug levels ... (CYP)-mediated,drug metabolism. These increased drug levels can ...
Cached Medicine Technology:Cell Therapeutics and IDIS Announce Agreement for a European Named Patient/Compassionate Use Program for Pixantrone 2Cell Therapeutics and IDIS Announce Agreement for a European Named Patient/Compassionate Use Program for Pixantrone 3Cell Therapeutics and IDIS Announce Agreement for a European Named Patient/Compassionate Use Program for Pixantrone 4Cell Therapeutics and IDIS Announce Agreement for a European Named Patient/Compassionate Use Program for Pixantrone 5Sequoia Pharmaceuticals Presents Proof of Clinical Concept of SPI-452, a Novel Pharmacokinetic Enhancer 2Sequoia Pharmaceuticals Presents Proof of Clinical Concept of SPI-452, a Novel Pharmacokinetic Enhancer 3Sequoia Pharmaceuticals Presents Proof of Clinical Concept of SPI-452, a Novel Pharmacokinetic Enhancer 4Sequoia Pharmaceuticals Presents Proof of Clinical Concept of SPI-452, a Novel Pharmacokinetic Enhancer 5
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... Precision Aesthetics ... eight years. It was also the first provider of Exilis non-surgical fat reduction ... sought after procedures it has attracted a large International clientele. Many patients travel ...
(Date:7/31/2015)... ... 31, 2015 , ... Last week, the Mesothelioma Applied Research ... be accessed by visiting http://www.curemeso.org/store . , “Our new store features a ... whenever a product is purchased, the Meso Foundation receives a $5.00 donation,” said ...
(Date:7/31/2015)... ... ... Sculpted Contours Luxury Medical Aesthetics announces the arrival of the newest applicator ... new applicator in the United States as an upgrade to the CoolSmooth applicator cleared ... applicator required a 2 hour treatment time. The new CoolSmooth Pro reduces the ...
(Date:7/31/2015)... , ... July 31, 2015 , ... ... important workshop at its new True North Conference Center. The medical community, social ... the Jacksonville community may be more aligned in the effort to better understand ...
(Date:7/31/2015)... , ... July 31, 2015 , ... Coco Libre announced ... judges, media, and VIPs at the 2015 Vans US Open of Surfing, July 25 ... that can claim “no added sugar” on the market, is a natural choice given ...
Breaking Medicine News(10 mins):Health News:Mesothelioma Organization Launches New Store 2Health News:Mesothelioma Organization Launches New Store 3Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 3Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 2Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 3Health News:Coco Libre Brings Eco-conscious Hydration to Vans US Open of Surfing 2
... uterus, the more likely she is to have a miscarriage, ... Journal of Medicine details the most precise information the timing ... its success or failure. ,Fertilised eggs can attach themselves ... 12 days after ovulation, the researchers from the National Institute ...
... the chances of getting bowel cancer, say scientists. Swedish ... and say that it points more firmly than ever to ... Research Campaing and Swedish Cancer Foundation, combined and analysed the ... It found that people who exercised regulatly were 50% less ...
... resposible for infertility.The virus is called adeno-associated virus (AAV) ... from men whose semen was abnormal. The virus was ... those with normal semen. ,Dr Jorg Schlehofer, ... research, said the virus should be assessed further to ...
... blood disorder that affects red blood cells. People with ... an abnormal type of hemoglobin. Sometimes these red blood ... blood vessels. When sickle-shaped cells clump together and obstruct ... to require hospital admission. // ,Researchers from ...
... among the deadliest of cancers, affecting many people a year ... the most aggressive cancer and there are few palliative treatments. ... deadly pancreatic cancer cells in the test tube and in ... Dr. Paul B. Fisher, a professor of clinical pathology at ...
... widely used anticancer drug, hydroxyurea, shows potent colon cancer-killing ... researchers. The new compounds seem to be very interesting ... ,Previous drugs derived from hydroxyurea were extremely active in ... serious side effects. This prompted the researchers to synthesize ...
Cached Medicine News:
This multiple-function instrument allows the surgeon to grasp, coagulate, and transect tissue with a single instrument, eliminating the need for multiple instruments and, in some procedures, costly l...
Bipolar forceps...
... An in vitro Nucleic Acid ... using Microplate Chemiluminescence for the ... (HPV) Types 6,11,16,18,31,33,35,39,42,43,44,45,51,52,56,58,59 and 68 ... Lowand High-Risk Groups in Cervical ...
... superb radiation protection-0.62mm (+/- .05)Pb lead glass ... to their level of protection, they are ... smoothly on your bridge while hugging your ... wear corrective lenses, you can order Leaded ...
Medicine Products: